Paper

Tree Display

AceDB Schema

XML Display

Feedback

Paper Report for: Rosenstock_2006_Clin.Ther_28_1556

Reference

Title: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P
Ref: Clin Ther, 28:1556, 2006 : PubMed

        



Related information

Inhibitor | Sitagliptin,


Citations formats

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
Clin Ther 28: 1556-68

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P (2006)
Clin Ther 28: 1556-68



Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page
webmaster

Acknowledgements and disclaimer